메뉴 건너뛰기




Volumn 59, Issue 4, 2005, Pages 473-477

Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years

Author keywords

Alzheimer's disease (AD); Cholinesterase inhibitor; Long term efficacy; Mini mental state examination (MMSE); Rivastigmine

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

EID: 16344378591     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00524.x     Document Type: Review
Times cited : (87)

References (13)
  • 1
    • 0035826771 scopus 로고    scopus 로고
    • Practice parameter: Management of dementia (an evidence-based review). Report of the quality standards subcommittee of the american academy of neurology
    • Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the american academy of neurology. Neurology 2001; 56: 1154-66.
    • (2001) Neurology , vol.56 , pp. 1154-1166
    • Doody, R.S.1    Stevens, J.C.2    Beck, C.3
  • 2
    • 0034877979 scopus 로고    scopus 로고
    • Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success
    • Winblad B, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success. Int J Geriatr Psychiatry 2001; 16: 653-6.
    • (2001) Int. J. Geriatr. Psychiatry , vol.16 , pp. 653-656
    • Winblad, B.1    Brodaty, H.2    Gauthier, S.3
  • 3
    • 0016823810 scopus 로고
    • Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
    • Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
    • (1975) J. Psychiatr. Res. , vol.12 , pp. 189-198
    • Folstein, M.F.1    Folstein, S.E.2    McHugh, P.R.3
  • 6
    • 16344394107 scopus 로고    scopus 로고
    • Four years treatment with galantamine: Long-term cognition effects in Alzheimer's disease
    • (Abstract P2133)
    • Truyen L, Hammond G, Schwalen S. Four years treatment with galantamine: long-term cognition effects in Alzheimer's disease. Eur J Neurol 2003; 10 (Suppl. 11): 161 (Abstract P2133).
    • (2003) Eur. J. Neurol. , vol.10 , Issue.SUPPL. 11 , pp. 161
    • Truyen, L.1    Hammond, G.2    Schwalen, S.3
  • 7
    • 0031902795 scopus 로고    scopus 로고
    • A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
    • Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
    • (1998) Int. J. Geriatr. Psychopharmacol. , vol.1 , pp. 55-65
    • Corey-Bloom, J.1    Anand, R.2    Veach, J.3
  • 8
    • 0033528436 scopus 로고    scopus 로고
    • Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
    • Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-40.
    • (1999) BMJ , vol.318 , pp. 633-640
    • Rösler, M.1    Anand, R.2    Cicin-Sain, A.3
  • 9
    • 0034046848 scopus 로고    scopus 로고
    • Dose-response effect of rivastigmine in the treatment of Alzheimer's disease
    • Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriat Psychopharm 2000; 2: 68-72.
    • (2000) Int. J. Geriat. Psychopharm. , vol.2 , pp. 68-72
    • Anand, R.1    Messina, J.2    Hartman, R.3
  • 11
    • 18544403400 scopus 로고    scopus 로고
    • Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review
    • Bryant J, Clegg A, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137.
    • (2001) Health Technol. Assess. , vol.5 , pp. 1-137
    • Bryant, J.1    Clegg, A.2    Nicholson, T.3
  • 13
    • 0033755037 scopus 로고    scopus 로고
    • Use of donepezil for the treatment of mild-moderate Alzheimer's disease: An audit of the assessment and treatment of patients in routine clinical practice
    • Cameron I, Curran S, Newton P, Petty D, Wards J. Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice. Int J Geriatr Psychiatry 2000; 15: 887-91.
    • (2000) Int. J. Geriatr. Psychiatry , vol.15 , pp. 887-891
    • Cameron, I.1    Curran, S.2    Newton, P.3    Petty, D.4    Wards, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.